Introduction
============

Typical features of type 2 diabetes mellitus (T2DM) are insulin resistance of various organs such as liver, muscle and adipose tissue, abnormal hepatic glucose production and reduced glucose-stimulated insulin secretion.^[@bib1]^ This panel of characteristics is caused at least in part by insensitivity of the insulin receptor and impairment of insulin signalling. In the early stages of developing T2DM, pancreatic insulin production increases to overcome resistance. However, during progression of T2DM, insulin secretion decreases owing to the depletion of pancreatic β-cells, resulting in absolute insulin deficiency and increase in plasma glucose levels.^[@bib2]^ Long-term elevated plasma glucose levels are responsible for the development of microvascular complications, such as retino-, nephro- and neuropathy, and macrovascular complications, such as atherosclerosis, which are the most common long-term complications of T2DM.^[@bib3],\ [@bib4]^ Correcting insulin resistance and substituting insulin currently is regarded as the gold standard of diabetes therapy. In addition, several medications are available ([Table 1](#tbl1){ref-type="table"}), which improve glucose utilization and uptake into insulin-sensitive tissues^[@bib5]^ such as metformin^[@bib6]^ and rosi- and pioglitazone.^[@bib7]^ Release of insulin from pancreatic stores is achieved by sulphonylureas^[@bib8]^ or incretin mimetics such as glucagon-like peptide 1 analogues and dipeptidyl peptidase 4 inhibitors.^[@bib9]^ A major disadvantage of most of these interventions is that the daily dietary calorie intake usually stays too high and, thus, progression of T2DM is supported.^[@bib10]^ In addition, only 50% of patients with T2DM reach glycaemic control with currently available therapy options.^[@bib11],\ [@bib12]^ Many of the current T2DM treatments have dose-limiting safety or tolerability issues, including hypoglycaemia (sulphonylureas), oedema (glitazones), weight gain (sulphonylureas, glitazones) or gastrointestinal adverse events (glucagon-like peptide 1 analogues). Therefore, a medical need for therapies with lesser side effects, which in addition increase glycaemic control, becomes evident. These considerations led to the clinical development of a new class of antidiabetic drugs: inhibitors of the renal sodium-linked glucose transporter 2 (SGLT2).^[@bib13]^ This approach aims at therapeutically induced glucose excretion with urine. It combines two medical needs: glycaemic control and reduction of already ingested calories (as glucose is secreted unmetabolized). For physicians, this is a new approach. Throughout the following, we review the molecular mechanism of action, regulatory status, efficacy and safety of SGLT2 inhibitors with focus on canagliflozin.

Regulation of glucose homeostasis by the kidneys
================================================

The kidneys regulate the homeostasis of numerous substances of the body. In addition to the regulation of protein, mineral and acid--base balance, the kidneys have a crucial role in the control of energy homeostasis.^[@bib14]^ Especially, the role of the kidneys in glucose metabolism is important and includes, in addition to gluconeogenesis and glucose utilization, glucose filtration and reabsorption.^[@bib15]^ Owing to its low molecular weight, ingested glucose is filtered into primary urine and is recovered by the kidneys. Daily dietary glucose intake (\~180 g) is filtered and recovered afterwards. This mechanism was important for survival in times of food scarcity. Glucose recovery is mediated by a tubular transport system that can reabsorb glucose in combination with sodium (sodium-linked glucose transporter 1 and 2, SGLT1 and 2, respectively).^[@bib16]^ This mechanism is not a unique feature of renal tubules, but also exists in other organs, such as the intestine. Whereas in the gastrointestinal tract especially *SLC5A1* (SGLT1) is expressed, renal tubules express *SLC5A1* and *SLC5A2* (SGLT2).^[@bib17]^ An overview of all known SGLT transporters and their tissue distribution is depicted in [Table 2](#tbl2){ref-type="table"}.

Both transporters are able to reabsorb glucose. However, they show significant differences in affinities and transport capacity: SGLT2 has a greater transport capacity and reabsorbs glucose in combination with sodium in the ratio 1:1. SGLT1 has a higher affinity for glucose and reabsorbs glucose in combination with sodium in the ratio 1:2.^[@bib17],\ [@bib18]^ These different transport properties are used by the kidneys to reabsorb all energy, leading to glucose-free urine. SGLT2 is localized mainly in the first two segments of the proximal tubular system (S1 and S2 segment). Owing to its high transport capacity, it is capable of reabsorbing about 90% of glucose from the primary urine. Ten percent of initially filtered glucose is recovered in the third section of the proximal tubule (S3 segment) by SGLT1 because of its high affinity. Both transporters are secondarily active owing to their dependence on the activity of the Na^+^/K^+^-ATPase in the basolateral membrane for the active removal of sodium. Glucose transporters (GLUT2 and GLUT1) facilitate glucose transport across the basolateral membrane in the early and more distal regions of the proximal tubule^[@bib17]^ ([Figure 1](#fig1){ref-type="fig"}).

There are certain mechanisms of compensation in cases of a surplus or failure of a transporter system. Diabetic patients, for example, have an increased glucose excretion in the primary urine. In this case, *SLC5A2* expression is often increased, leading to an increase in the renal threshold for glucose in the final urine.^[@bib19]^ As a consequence, the kidneys also retain body glucose under diabetic conditions. On the other hand, an inhibition of SGLT2 reduces glucose reabsorption in the S1 and S2 segments and can be compensated only in part by SGLT1 in the S3 segment so that complete reabsorption of glucose is not warranted.^[@bib20]^ Under physiological circumstances, this dual mechanism of reabsorption allows the careful handling of an important energy source, namely glucose.

On the basis of this knowledge, a new therapeutic principle for the treatment of T2DM was developed.^[@bib13]^ Inhibition of the SGLT transport system results in increased urinary glucose excretion due to reduced glucose reabsorption. As a consequence plasma glucose levels are lowered, resulting in loss of calories and antihyperglycaemic effects beneficial for patients with T2DM.

Regulatory status of SGLT2 inhibitors
=====================================

Different SGLT2 inhibitors, also called gliflozins, are currently marketed or are undergoing clinical development and approval procedures ([Table 3](#tbl3){ref-type="table"}). In November 2012, the first-in-class SGLT2 inhibitor, dapagliflozin (Forxiga), was granted a marketing authorization by the European Medicines Agency (EMA). Dapagliflozin was initially rejected by the US Food and Drug Administration (FDA) owing to concerns noted by an Advisory Panel about potential increases in the risk of bladder and breast cancers associated with the drug.^[@bib21]^ In January 2014, FDA granted marketing authorization for dapagliflozin (Farxiga) after new safety data on dapagliflozin from ongoing studies were provided. The FDA required to perform several post-marketing studies, in which \>17 000 patients will be followed for 4--5 years to clarify whether dapagliflozin therapy is associated with increased risks for cardiovascular (CV) events, liver toxicity or cancer. Other post-marketing studies are required by the FDA to further assess bladder cancer risk and dapagliflozin\'s effect in paediatric patients. Furthermore, an intense pharmacovigilance programme to monitor reports of liver toxicity and pregnancy outcomes has to be implemented by the company. Canagliflozin (Invokana) was approved by the FDA in March 2013, and in November 2013 by the EMA. Marketing authorizations followed a positive opinion of Advisory Committees, but concerns about safety of canagliflozin remained, which are addressed in several post-authorization safety studies (please also refer to the section on safety of SGLT2 inhibitors for details). In Europe, canagliflozin is labelled with an inverted black triangle in the package leaflet and the summary of product characteristics (SmPC),^[@bib22]^ indicating that the drug is under additional monitoring by regulatory authorities. On March 2014, the EMA recommended granting of a marketing authorization for a third SGLT2 inhibitor empaglifozin (Jardiance), and in May 2014 the European Commission followed the positive vote of the EMA. Initially, FDA rejected approval of empagliflozin in March 2014 owing to previously observed deficiencies at a facility where empagliflozin is manufactured, but finally approved it in August 2014. In Japan four SGLT2 inihibitors, namely dapagliflozin, ipragliflozin, tofogliflozin and luseogliflozin, were approved in 2014 ([Table 3](#tbl3){ref-type="table"}).

Pharmacokinetics of canagliflozin
=================================

For gliflozins, comprehensive data from phase II and III clinical trials are available.^[@bib23]^

Throughout the following sections, we focus exemplarily on canagliflozin as the first SGLT2 inhibitor licensed in the US and Europe.

Canagliflozin has an oral bioavailability of 65% with a maximum effect after 30--120 min. Its pharmacokinetic profile is independent of age, body weight, gender, ethnicity, administration with food and mild-to-moderate hepatic impairment. Importantly, the amount of glucose filtered in the glomerulus depends not only on plasma glucose levels but also on the glomerular filtration rate (GFR). Therefore, it can be expected that with decreasing renal function a decrease of activity is paralleled. Unlike with other antidiabetic drugs, such as metformin or glimepiride, with impaired renal function there is no risk to the patient, but the treatment becomes gradually ineffective. As a consequence, canagliflozin therapy should not be initiated in patients with end-stage renal disease, on dialysis, or with renal impairment at an eGFR\<60 ml^--1^ min^--1^ per 1.73 m^2^. Clinical trials^[@bib24]^ confirmed that significant glycaemic efficacy still was observed in subjects with eGFR values of *⩾* 30 to \<50 ml^--1^ min^--1^ per 1.73 m^2^, even though the reductions in glycosylated haemoglobin A~1c~ (HbA~1c~) and fasting plasma glucose were smaller than seen in subjects with higher baseline eGFR values (see section below). In canagliflozin-treated patients whose eGFR falls below 60 ml^--1^ min^--1^ per 1.73 m^2^, canagliflozin dose should be adjusted to or maintained at the low dose of 100 mg once daily. Approximately 40% of administered canagliflozin is excreted unmetabolized in faeces; minor metabolism of canagliflozin occurs via uridine 5\'-diphospho-glucuronosyltransferase, resulting in two pharmacologically inactive metabolites (canagliflozin O-glucuronides) mainly excreted via urine. With a half-life of 11--13 h a once-daily regimen is therapeutically sufficient (SmPC Invokana^[@bib22]^).

Pharmacology of canagliflozin---effects on glucose metabolism, body weight and the CV system
============================================================================================

Canagliflozin is a competitive, reversible, highly selective SGLT2 inhibitor with a 250-fold selectivity towards SGLT2 over SGLT1. Inhibition of SGLT2 by canagliflozin leads to a reduction of glucose reabsorption from primary urine. The induced glucosuria of \~70 g per day results in a loss of glucose and optimized plasma glucose control.^[@bib20],\ [@bib25]^ Canagliflozin is indicated in patients with T2DM to improve glycaemic control as monotherapy when diet and exercise alone do not provide adequate glycaemic control and in patients for whom the use of metformin is considered inappropriate owing to intolerance or contraindications. Furthermore, it is indicated as add-on therapy with other antihyperglycaemic medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (SmPC Invokana^[@bib22]^). [Table 4](#tbl4){ref-type="table"} summarizes the efficacy data of canagliflozin derived from phase III clinical trials. Canagliflozin is used at doses of 100 or 300 mg and the primary end point in the pivotal studies was lowering HbA~1c~. Serving as secondary end points, effects on fasting plasma glucose, body weight, blood pressure and lipid parameters were investigated.

As reflected in the European Public Assessment Report (EPAR) of canagliflozin,^[@bib26]^ 7803 subjects were randomized. This included 4994 subjects treated with canagliflozin (100 or 300 mg), 1583 treated with placebo and 1226 treated with an active comparator (744 sitagliptin, 482 glimepiride). Taken together, depending on the premedication and baseline HbA~1c~ placebo-adjusted reduction, between −0.57% and −0.91% (100 mg dose) and −0.70% and −1.16% (300 mg dose) was observed, respectively. In poorly controlled diabetic patients even a reduction of up to -- 2.42% was achieved. The favourable effect on HbA~1c~ values was consistent with an improvement of secondary end points such as fasting plasma glucose. The efficacy of canagliflozin was reduced in patients with moderate renal impairment. A meta-analysis of all subjects from placebo-controlled phase III studies with eGFR⩾30 to \<60 ml^--1^ min^--1^ per 1.73 m^2^ (1085 subjects) showed a decrease in HbA~1c~ from baseline by −0.47% and −0.38% for canagliflozin 300 and 100 mg, respectively, compared with placebo.^[@bib26]^ This is in line with the mode of action (see sections above) and is reflected in the SmPC^[@bib22]^ as a warning for patients with end-stage renal disease, on dialysis, or with renal impairment and an eGFR \<60 ml^--1^ min^--1^ per 1.73 m^2^.

The improvement in glycaemic control in T2DM patients achieved by SGLT2 inhibition also led to the consideration to use SGLT2 inhibitors in conjunction with insulin therapy in type 1 diabetes mellitus. So far, only limited data from studies with type 1 diabetic patients are available. Studies with empagliflozin in streptozotocin-induced diabetic rats^[@bib27]^ and results from a Phase II trial indicate beneficial effects of SGLT2 inhibition on reducing HbA~1c~, body weight, total daily insulin dose and hypoglycaemic events.^[@bib28]^ Further studies with empagliflozin and other SGLT2 inhibitors are currently underway to prove their efficacy and safety in type 1 diabetes mellitus patients.

Canagliflozin therapy not only was effective in improving glucose metabolism. The induced glucosuria of 70 g per day additionally leads to an energy deficit of 300 kcal per day, which translates into a body weight reduction of −1.84 and −2.43 kg (100 and 300 mg canagliflozin, respectively).^[@bib26]^ Interestingly, weight loss stabilizes after a couple of weeks, even so glucosuria persists and calorie loss is maintained. Compensatory mechanisms such as increased food intake might explain these findings. That weight loss was indeed caused by loss of fat mass and not osmotic diuresis could be shown by dual-energy X-ray absorptiometry body composition analysis in clinical trials,^[@bib29],\ [@bib30]^ a diagnostic technique that can distinguish between fat, bone mineral and other fat-free mass that does not include bone. The weight-reducing characteristics of SGLT2 inhibitors in T2DM patients also might be effective in non-diabetic overweight subjects. This not only creates the option to widen the indication for the use of SGLT2 inhibitors as antiobesity drugs, but also poses the risk for drug abuse, for instance, as a weight-reducing agent or doping compound.

Under canagliflozin therapy, a clinically relevant lowering of systolic (−3.9 and −5.3 mmHg for the 100 and 300 mg dose, respectively) and diastolic (−2.1 and −2.5 mm Hg for the 100 and 300 mg dose, respectively) blood pressure was observed in placebo-controlled studies, which is a desirable additional effect of canagliflozin and not usually expected for a glucose-lowering drug. This was not accompanied by an increased compensatory heart rate. Blood pressure reduction correlates with a mild diuretic effect and haemoconcentration (reflected by increased haemoglobin and haematocrit) observed during canagliflozin treatment.^[@bib22],\ [@bib31]^ Whether the renin--angiotensin--aldosterone system is counter-regulatory activated upon canagliflozin treatment as observed in patients with genetic loss of *SLC5A2* (familial renal glucosuria)^[@bib32]^ is currently under investigation.

T2DM usually entails marked long-term clinical consequences such as blindness and neuropathies derived from micro- or macroangiopathy. The question whether these hazardous clinical consequences can be reduced by canagliflozin therapy is currently under investigation and can, thus, not be answered conclusively at present.

Safety of canagliflozin
=======================

Among the most important safety aspects of antidiabetic drugs is their low propensity to induce hypoglycaemia. Interestingly, during clinical development of SGLT2 inhibitors hardly any hypoglycaemia was observed due to the following reasons: first, glucose excretion decreases along with decreasing plasma glucose levels and; second, counter-regulatory mechanisms are not affected by SGLT2 inhibition as gliflozins act independently from insulin. This low risk for hypoglycaemia can be regarded an advantage of this class of medicines as compared with classical antidiabetic compounds such as insulin or sulphonylureas.

The adverse events observed with canagliflozin reflect its pharmacodynamic action. Almost no organ toxicities were found during pre-clinical development;^[@bib26]^ only in long-term rat studies toxicities in terms of excessive bone growth (hyperostosis) and renal tubular tumours were observed, probably caused by undesired SGLT1 inhibition in the gastrointestinal tract and subsequent carbohydrate malabsorption. However, this is regarded as a species-specific phenomenon, as in rats canagliflozin is poorly absorbed from the gut and hence high local concentrations are reached, which are able to inhibit SGLT1 located at the surface of the intestinal mucosa. Carbohydrate malabsorption is accompanied by increased calcium absorption from the gut, probably causing hyperostosis and renal tubular tumours in the rat.

Nevertheless, SGLT2 inhibition can lead to unexpected sequels. It appears logical that glucosuria, deliberately induced by SGLT2 inhibition, favours urinary tract infections, as glucose serves as nutrient for bacteria. Some increase in urinary tract infections was indeed observed in regulatory safety trials; however, serious cases were rare.^[@bib33]^ Much more pronounced were canagliflozin-related increases in female mycotic genital infections. Infections are not serious in nature and easy to treat, but patients and prescribers should be aware of it. Another reported side effect of canagliflozin treatment is osmotic diuresis and subsequent water loss. However, unlike that observed during classical osmotic diuresis, where sodium is retained, SGLT2 inhibition causes sodium loss. This can be attributed to the fact that sodium is co-transported with glucose by SGLT2 ([Figure 1](#fig1){ref-type="fig"}). In fact, canagliflozin leads to a decrease in blood pressure and haemoconcentration, reflected by increased haemoglobin and haematocrit (increased levels of plasma lipoproteins could also be a consequence of it, see below), but notably no hypernatraemia as a trigger for thirst. The latter may explain why, in particular, elderly patients do not develop sufficient thirst to compensate for water loss and consequently tend to have dehydration, unstable blood pressure or syncope.^[@bib34],\ [@bib35]^ A rather sharp decrease in blood pressure can particularly occur at the beginning of therapy; later on, counter-regulatory mechanisms like reduction in glomerular perfusion minimize diuresis and blood pressure reduction. In order to avoid haemodynamic problems in vulnerable patients, canagliflozin therapy should be initiated with the lower dose of 100 mg per day (instead of 300 mg per day). Consequently, concomitant use of canagliflozin and loop diuretics is not recommended.^[@bib22]^

Regarding kidney function, there was intensive discussion during the licensing procedures whether canagliflozin might damage kidneys, especially when kidney function is already impaired by diabetic nephropathy.^[@bib26]^ The above-mentioned haemoconcentration observed under canagliflozin therapy also leads to an increase in serum creatinine, which is usually a marker for renal damage. However, it could be shown that its increase with canagliflozin treatment is fully reversible after cessation, so that renal damage can be excluded. Contrarily, canagliflozin may help protect kidneys because it appears to reduce GFR by reducing intra-glomerular pressure and hence might retard glomerular sclerosis. This possibility is currently under investigation.^[@bib36]^

There was also a discussion on the cancer risk of SGLT2 inhibitors. In phase III studies with the first SGLT2 inhibitor that was applied for marketing authorization, dapagliflozin, a marked numerical imbalance in the cases of bladder cancer was observed between the dapagliflozin and comparator groups; however, the number of cases was low. From 5501 patients under dapagliflozin 9 (0.16%) suffered from bladder cancer, whereas in the placebo group 1 of 3184 patients was affected (0.03%).^[@bib21],\ [@bib37]^ Reassuringly, no increase in bladder cancer was found subsequently with the other SGLT2 inhibitors, so that a chance finding is most likely.^[@bib38]^ Carcinogenicity studies in animals were conducted with all SGLT2 inhibitors under development. For dapagliflozin, no tumours were observed in these studies.^[@bib37]^ Canagliflozin caused certain types of tumours (for example, renal tubular tumours) in rats, but mechanistic studies revealed that off-target inhibition of SGLT1 in these animals was the underlying mechanism.^[@bib26]^

For canagliflozin, a long-term CV safety study is ongoing (CANVAS), which was originally planned to demonstrate CV safety in patients with increased risk for CV events ([Table 4](#tbl4){ref-type="table"}).^[@bib39]^ According to the present knowledge from a meta-analysis of clinical trials including an interim analysis of the CANVAS study provided in the EPAR of canagliflozin,^[@bib26]^ canagliflozin does not increase the overall CV risk. Notably, in patients without CV disease, canagliflozin-treated patients performed numerically better than the comparator therapies in respect to major CV events; the point estimate for the hazard ratio was 0.52, albeit with a broad 95% confidence interval, including 1.^[@bib26]^ This positive effect (if confirmed) could be related to the blood pressure-lowering effect of canagliflozin. On the other hand, in patients with existing CV disease the decrease in blood pressure, which is most pronounced immediately after onset of therapy, could be hazardous and could hence abolish the positive effect. For instance, the incidence of non-fatal stroke was numerically increased in the canagliflozin groups; further data from the CANVAS trial will show whether this effect is true. Also relevant for assessing CV safety is the plasma lipid profile; it turned out that canagliflozin (and also other SGLT2 inhibitors) slightly increased the levels of both high-density lipoprotein and low-density lipoprotein cholesterol.^[@bib33]^ This simultaneous increase of both lipoproteins might be a consequence of the observed haemoconcentration (see above) and probably does not imply increased CV risk.

Further information on CV risk and also on other safety issues, for example, long-term renal safety, safety in special populations, and---as far as possible---tumour incidence, is expected from ongoing trials.

Conclusion
==========

SGLT2 inhibitors are a promising new class of antidiabetic drugs currently approved in Europe, the US and Japan. They allow weight-reducing and effective glycaemic control combined with a low risk of hypoglycaemia. The medication can be used in any stage of the disease independently of existing co-medications. Furthermore, the use of SGLT2 inhibitors in addition to insulin therapy in type 1 diabetic patients is conceivable, for example, to improve their glycaemic profile and avoid hyperglycaemia. However, whether SGLT2 inhibitor therapy also improves the clinical consequences of diabetes, such as micro- or macrovascular late complications, cannot be answered at present owing to immature clinical data, and provides some uncertainty of this class of drugs. Caution with these drugs should be exercised in elderly patients (tendency to dehydration and urinary-, genital infections), patients with recurrent urinary tract or genital infections and patients with reduced renal function (reduced efficacy).

This review article was supported by intramural funding of the Federal Institute for Drugs and Medical Devices.

**Author Contributions**

BH, NE and PM wrote the manuscript. BH, MDSH and VP prepared figures and tables. All authors read and approved the final manuscript.

**Disclaimer**

The opinions mentioned throughout the following article are personal views of the authors and do not reflect an official position of the Federal Institute for Drugs and Medical Devices.

The authors declare no conflict of interest.

![Schematic overview depicting the localization and function of SGLT1 and SGLT2 in the kidneys. SGLT2 reabsorbs glucose in combination with sodium in a 1:1 ratio in the tubular S1 segment, whereas SGLT1 reabsorbs glucose in combination with sodium in a 1:2 ratio in the tubular S3 segment. Both transporters are secondary active and driven by the activity of the Na^+^/K^+^-ATPase. Glucose reuptake into blood vessels is facilitated by glucose transporters GLUT1 and GLUT2.](nutd201440f1){#fig1}

###### Overview of currently available antidiabetic medications

  *Class of antidiabetic drug*          *Mode of action*                                                                                                                                                                                                                                             *Target organ/tissue*                                   *Marketed drugs*[a](#t1-fn2){ref-type="fn"}
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  α-Glucosidase inhibitors              Competitive inhibition of α-glucosidase: reduction of enzymatic degradation of polysaccharids in the intestine and in consequence reduced glucose uptake                                                                                                     Intestine                                               Acarbose, Miglitol
  Biguanides                            AMPK activation and mGPD inhibition: inhibition of gluconeogenesis, increased glucose uptake and fatty-acid oxidation; additional effects: reduction of glucose absorption from intestine, increase of insulin sensitivity, appetite suppressant             e.g., liver, muscle, kidney                             Metformin
  Gliflozines (SGLT2 inhibitors)        SGLT2 inhibition: reduction of glucose reabsorption in kidney leads to increased glucose excretion via urine                                                                                                                                                 Renal proximal tubule                                   Canagliflozin, Dapagliflozin, Empagliflozin
  Glinides                              Sulphonylurea analogues with different pharmacokinetics: glucose-independent insulin release from pancreatic β-cells                                                                                                                                         Pancreatic β-cells                                      Nateglinide, Repaglinide
  Gliptines (DPP4 inhibitors)           Inhibition of DPP4: delay of enzymatic incretine degradation                                                                                                                                                                                                 e.g., kidney, intestine, lung, vascular walls, plasma   Alogliptin, Linagliptin, Saxagliptin, Sitagliptin, Vildagliptin
  Incretine mimetics (GLP1 analogues)   GLP1 receptor agonists: increased glucose sensitivity of β-cells, increased insulin sensitivity in target tissues due to removal of glucose toxicity, decreased glucagon secretion from α-cells, delayed gastric emptying and increased feeling of satiety   e.g., insulin target tissues, pancreas, CNS             Albiglutide, Exenatide, Liraglutide, Lixisenatide
  Sulphonylurea                         Glucose-independent insulin release from pancreatic β-cells                                                                                                                                                                                                  Pancreatic β-cells                                      1st generation: Chlorpropamide, Tolbutamide 2nd generation: Glibenclamide, Gliclazide, Glipizide, Gliquidone 3rd generation: Glimepiride
  Thiazolidinediones (Glitazones)       PPARγ agonists: insulin-sensitizing effect on liver, muscle and adipose tissue; increased adipocyte differentiation                                                                                                                                          Liver, muscle, adipose tissue, CNS                      Pioglitazone, Rosiglitazone

Abbreviations: AMPK, 5\' adenosine monophosphate-activated protein kinase; CNS, central nervous system; DPP4, dipeptidyl peptidase 4; GLP1, glucagon-like peptide 1; mGPD, glycerophosphate dehydrogenase; PPARγ, peroxisome proliferator-activated receptor γ SGLT2, sodium-linked glucose transporter 2.

Most prominent drugs marketed in the United States and/or Europe.

###### Substrates, substrate affinities and tissue distribution of *SCL5* genes and the respective SGLT/SMIT transporter

  *Gene (transporter)*           *Substrate*                                           *Apparent affinity, K*~*0.5*~ *(m[M]{.smallcaps})*  *Tissue expression*
  ------------------------------ ---------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------
  *SLC5A1* (hSGLT1)              [D]{.smallcaps}-Glucose                                                      0.5                          Intestine, trachea, kidney, heart, brain, testis and prostate
                                 [D]{.smallcaps}-Galactose                                                     1                            
  *SLC5A2* (hSGLT2)              [D]{.smallcaps}-Glucose                                                       5                           Kidney, brain, liver, thyroid, muscle and heart
                                 [D]{.smallcaps}-Galactose                                                   \>100                          
  *SLC5A3* (cSMIT1)              Myo-inositol                                                                0.050                         Brain, heart, kidney and lung
                                 [D]{.smallcaps}-Glucose                                                      \>50                          
  *SLC5A4* (hSGLT3)              [D]{.smallcaps}-Glucose, Miglitol                                         19, 0.003                       Brain, intestine, kidney, lung, muscle, testis and uterus
  *SLC5A9* (hSGLT4)              [D]{.smallcaps}-Glucose, [D]{.smallcaps}-Mannose                          7.7, 0.15                       Intestine, kidney liver, brain, lung, trachea, uterus and pancreas
  *SLC5A10* (hSGLT5)             [D]{.smallcaps}-Glucose, [D]{.smallcaps}-Galactose                        Not known                       Kidney
  *SLC5A11* (rtSMIT2, rtSGLT6)   Myo-inositol                                                                 0.27                         Brain, kidney and intestine
                                 [D]{.smallcaps}-Glucose                                                       36                           

Abbreviations: c, canine; h, human; rt, rat.

Substrate specificity, apparent affinity (K~0.5~ for the substrates) and tissue distribution according to (16;17;40--47).

###### Overview of the current regulatory status of SGLT inhibitors for the treatment of diabetes

  *SGLT inhibitor*   *Trial registration number*   *Daily dose*         *Approval/developmental status*                            *SGLT selectivity*
  ------------------ ----------------------------- -------------------- ---------------------------------------------------------- --------------------
  Dapagliflozin      NA                            5, 10 mg             Approved by EMA (2012/11), FDA (2014/01), PMDA (2014/03)   SGLT2
  Canagliflozin      NA                            100, 300 mg          Approved by FDA (2013/03), EMA (2013/11)                   SGLT2
  Empagliflozin      NA                            10, 25 mg            Approved by EMA (2014/05), FDA (2014/08)                   SGLT2
  Ipragliflozin      NA                            25, 50 mg            Approved by PMDA (2014/01)                                 SGLT2
  Tofogliflozin      NA                            20 mg                Approved by PMDA (2014/3)                                  SGLT2
  Luseogliflozin     NA                            2.5, 5 mg            Approved by PMDA (2014/03)                                 SGLT2
  Ertugliflozin      NCT01958671                   5, 10 mg             Phase III recruiting                                       SGLT2
  LX4211             NCT01742208                   Not yet determined   Phase II                                                   SGLT1/SGLT2
  GSK189075          NCT00500331                   Not yet determined   Phase II                                                   SGLT2
  EGT0001442         NCT01377844                   Not yet determined   Phase II                                                   SGLT2
  BI 44847           NCT00558909                   Not yet determined   Phase I                                                    SGLT2
  EGT0001474         NCT00924053                   Not yet determined   Phase I                                                    SGLT2
  GSK-1614235        NCT01607385                   Not yet determined   Phase I                                                    SGLT1
  ISIS-SGLT2Rx       NCT00836225                   Not yet determined   Phase I                                                    SGLT2

Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration; NA, not applicable; PMDA, Pharmaceuticals and Medical Devices Agency.

Japan; source of information: homepages of the FDA,^[@bib48]^ EMA,^[@bib22]^ PMDA,^[@bib49]^ ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)).

###### Efficacy data of canagliflozin in phase III clinical trials

  *Trial registration number/study type*                                                                            *Design, duration (duration to primary end point/duration of extension phase)*   *Intervention*                            *No. subjects per treatment arm (ITT)*   *Primary end point*                          *Baseline HbA*~*1c*~ *(%), mean*±*s.d.*   *Change in HbA*~*1c*~ *from baseline (%), LS mean (SE)*
  ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------- ---------------------------------------- -------------------------------------------- ----------------------------------------- ---------------------------------------------------------
  *Monotherapy*[a](#t4-fn3){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                     
  NCT01081834,^[@bib50],[@bib51]^ main study[b](#t4-fn4){ref-type="fn"} monotherapy (90 centres)                    PC, PG 52 wks (26 wks/26 wks)                                                    Placebo                                   192                                      Δ BL to wk 26 in HbA~1c~                     7.97±0.955                                0.14±0.065
                                                                                                                                                                                                     Canagliflozin 100mg                       195                                                                                   8.06±0.959                                −0.77±0.065
                                                                                                                                                                                                     Canagliflozin 300mg                       197                                                                                   8.01±0.988                                −1.03±0.064
                                                                                                                    52 wks extension period                                                          Canagliflozin 100mg                       191                                      Δ BL to wk 52 in HbA~1c~                     8.06±0.959                                −0.75±0.067
                                                                                                                                                                                                     Canagliflozin 300mg                       194                                                                                   8.01±0.988                                −1.04±0.067
  High glycaemic substudy monotherapy (40 centres)                                                                  PG 26 wks (26 wks/no extension)                                                  Canagliflozin 100mg                       47                                       Δ BL to wk 26 in HbA~1c~                     10.59±0.873                               −2.13±0.220
                                                                                                                                                                                                     Canagliflozin 300mg                       44                                                                                    10.62±0.955                               −2.56±0.227
                                                                                                                                                                                                                                                                                                                                                                                
  *Add-on to AHA monotherapy*[a](#t4-fn3){ref-type="fn"}                                                                                                                                                                                                                                                                                                                       
  NCT01106677[b,](#t4-fn4){ref-type="fn"}^[@bib52]^ add-on to metformin monotherapy (169 centres)                   PC, AC, PG 52 wks (26 wks/26 wks)                                                Placebo                                   183                                      Δ BL to wk 26 in HbA~1c~                     7.96±0.896                                −0.17±0.060
                                                                                                                                                                                                     Canagliflozin 100mg                       368                                                                                   7.94±0.879                                −0.79±0.044
                                                                                                                                                                                                     Canagliflozin 300mg                       367                                                                                   7.95±0.931                                −0.94±0.044
                                                                                                                                                                                                     Sitagliptin 100mg                         366                                                                                   7.92±0.875                                −0.82±0.044
                                                                                                                    52-wks extension period                                                          Canagliflozin 100mg                       365                                      Δ BL to wk 52 in HbA~1c~                     7.94±0.879                                −0.73±0.047
                                                                                                                                                                                                     Canagliflozin 300mg                       360                                                                                   7.95±0.931                                −0.88±0.047
                                                                                                                                                                                                     Sitagliptin 100mg                         354                                                                                   7.92±0.875                                −0.73±0.047
  NCT00968812,^[@bib30]^ add-on to metformin monotherapy (157 centres)                                              AC, PG 104 wks (52 wks/52 wks)                                                   Canagliflozin 100mg                       483                                      Δ BL to wk 52 in HbA~1c~                     7.78±0.787                                −0.82±0.039
                                                                                                                                                                                                     Canagliflozin 300mg                       485                                                                                   7.79±0.779                                −0.93±0.039
                                                                                                                                                                                                     Glimepiride (titrated from 1--6 or 8mg)   482                                                                                   7.83±0.795                                −0.81±0.039
                                                                                                                                                                                                                                                                                                                                                                                
  *Add-on to dual-combination AHA therapy*[a](#t4-fn3){ref-type="fn"}                                                                                                                                                                                                                                                                                                          
  NCT01106625, add-on to metformin+sulphonylurea (85 centres)                                                       PC, PG 52 (26 wks/26 wks)                                                        Placebo                                   156                                      Δ BL to wk 26 in HbA~1c~                     8.12±0.896                                −0.13±0.075
                                                                                                                                                                                                     Canagliflozin 100mg                       157                                                                                   8.13±0.926                                −0.85±0.075
                                                                                                                                                                                                     Canagliflozin 300mg                       156                                                                                   8.13±0.942                                −1.06±0.076
                                                                                                                    52-wks extension period                                                          Placebo                                   150                                      Δ BL to wk 52 in HbA~1c~                     8.12±0.896                                −0.01±0.077
                                                                                                                                                                                                     Canagliflozin 100mg                       155                                                                                   8.13±0.926                                −0.74±0.077
                                                                                                                                                                                                     Canagliflozin 300mg                       152                                                                                   8.13±0.942                                −0.97±0.078
  NCT01106690,[b](#t4-fn4){ref-type="fn"} add-on to metformin+pioglitazone (74 centres)                             PC, PG 52 wks (26 wks/26 wks)                                                    Placebo                                   115                                      Δ BL to wk 26 in HbA~1c~                     8.00±1.010                                −0.26±0.069
                                                                                                                                                                                                     Canagliflozin 100mg                       113                                                                                   7.99±0.940                                −0.89±0.069
                                                                                                                                                                                                     Canagliflozin 300mg                       114                                                                                   7.84±0.911                                −1.03±0.070
  NCT01137812,^[@bib53]^ add-on to metformin+sulphonylurea (140 centres)                                            AC, PG 52 wks (52 wks/no extension)                                              Canagliflozin 300mg                       377                                      Δ BL to wk 52 in HbA~1c~                     8.12±0.910                                −1.03±0.048
                                                                                                                                                                                                     Sitagliptin 100mg                         378                                                                                   8.13±0.916                                −0.66±0.049
                                                                                                                                                                                                                                                                                                                                                                                
  *Special population studies*[a](#t4-fn3){ref-type="fn"}                                                                                                                                                                                                                                                                                                                      
  NCT01106651,^[@bib29]^ older adults (⩾55 to ⩽80 years of age) (90 centres)                                        PC, PG104 wks (26 wks/78 wks)                                                    Placebo                                   237                                      Δ BL to wk 26 in HbA~1c~                     7.76±0.785                                −0.03±0.063
                                                                                                                                                                                                     Canagliflozin 100mg                       241                                                                                   7.77±0.773                                −0.60±0.063
                                                                                                                                                                                                     Canagliflozin 300mg                       236                                                                                   7.69±0.779                                −0.73±0.064
  NCT01064414,^[@bib24]^ moderate renal impairment (eGFR ⩾30 to \<50 ml^--1^ min^--1^ per 1.73 m^2^) (89 centres)   PC, PG 52 wks (26 wks/26 wks)                                                    Placebo                                   90                                       Δ BL to wk 26 in HbA~1c~                     8.02±0.917                                −0.03±0.090
                                                                                                                                                                                                     Canagliflozin 100mg                       90                                                                                    7.89±0.898                                −0.33±0.090
                                                                                                                                                                                                     Canagliflozin 300mg                       89                                                                                    7.97±0.805                                −0.44±0.089
                                                                                                                    52-wks extension                                                                 Placebo                                   87                                       Δ BL to wk 52 in HbA~1c~                     8.02±0.917                                −0.07±0.104
                                                                                                                    Period                                                                           Canagliflozin 100mg                       89                                                                                    7.88±0.886                                −0.19±0.104
                                                                                                                                                                                                     Canagliflozin 300mg                       89                                                                                    7.97±0.805                                −0.33±0.103
                                                                                                                                                                                                                                                                                                                                                                                
  *Cardiovascular assessment study with efficacy substudies*[a](#t4-fn3){ref-type="fn"}                                                                                                                                                                                                                                                                                        
  NCT01032629, cardiovascular study (369 centres)                                                                   PC, PG duration is event driven based on number of MACE events                   Placebo                                   1441[c](#t4-fn5){ref-type="fn"}          Assessment of hazard ratio for MACE events                                              
                                                                                                                                                                                                     Canagliflozin 100mg                       1445[c](#t4-fn5){ref-type="fn"}                                                                                                  
                                                                                                                                                                                                     Canagliflozin 300mg                       1441[c](#t4-fn5){ref-type="fn"}                                                                                                  
  Insulin substudy (316 centres)                                                                                    PC, PG 18 wks (18 wks/no extension)                                              Placebo                                   565                                      Δ BL to wk 18 in HbA~1c~                     8.20±0.837                                0.01±0.032
                                                                                                                                                                                                     Canagliflozin 100 mg                      566                                                                                   8.33±0.905                                −0.63±0.031
                                                                                                                                                                                                     Canagliflozin 300 mg                      587                                                                                   8.27±0.894                                −0.72±0.030
  Sulphonylurea substudy (80 centres)                                                                               PC, PG 18 wks (18 wks/no extension)                                              Placebo                                   45                                       Δ BL to wk 18 in HbA~1c~                     8.49±1.130                                0.04±0.146
                                                                                                                                                                                                     Canagliflozin 100mg                       42                                                                                    8.29±0.831                                −0.70±0.145
                                                                                                                                                                                                     Canagliflozin 300 mg                      40                                                                                    8.28±1.005                                −0.79±0.147

Abbreviations: Δ, change from; AC, active-controlled; AHA, anti-hyperglycaemic agent; BL, baseline; eGFR, estimated glomerular filtration rate; ITT, intent-to-treat population; LS, least-squares; MACE, major adverse cardiovascular events; No., number; PC, placebo-controlled; PG, parallel group; QD, once daily; SU, sulphonylurea; wk(s), week(s).

Source of information: European Public Assessment Report (EPAR) of canagliflozin^[@bib26]^ if not otherwise indicated.

Double-blind and randomized.

Subjects assigned to placebo were switched to sitagliptin during the double-blind extension period.

Randomized and treated subjects (that is, safety analysis set).

[^1]: These authors contributed equally to this work.
